Bio-Path (NASDAQ:BPTH) Earns Sell Rating from Analysts at StockNews.com

Stock analysts at StockNews.com began coverage on shares of Bio-Path (NASDAQ:BPTH) in a research note issued to investors on Saturday. The brokerage set a “sell” rating on the stock.

Separately, Roth Mkm reaffirmed a “buy” rating and issued a $20.00 price objective on shares of Bio-Path in a report on Monday, July 8th.

Bio-Path Price Performance

BPTH opened at $0.89 on Friday. Bio-Path has a 1-year low of $0.88 and a 1-year high of $21.60. The company has a 50-day moving average of $1.37 and a 200-day moving average of $2.51.

Bio-Path (NASDAQ:BPTH) last announced its quarterly earnings data on Thursday, August 15th. The company reported ($1.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.54) by $0.38. During the same period last year, the firm posted ($10.60) EPS. On average, sell-side analysts anticipate that Bio-Path will post -6.2 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Bio-Path

An institutional investor recently bought a new position in Bio-Path stock. Armistice Capital LLC bought a new stake in shares of Bio-Path Holdings, Inc. (NASDAQ:BPTH) in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 97,000 shares of the company’s stock, valued at approximately $194,000. Armistice Capital LLC owned about 4.66% of Bio-Path at the end of the most recent quarter. 5.74% of the stock is owned by institutional investors and hedge funds.

About Bio-Path

Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.